Affiliation
Royal Albert Edward Infirmary, Wigan, Lancs.Issue Date
1994-08
Metadata
Show full item recordCitation
Staging of colorectal cancer. 1994, 49 (8):515-23 Clin RadiolJournal
Clinical RadiologyDOI
10.1016/S0009-9260(05)82928-9PubMed ID
7955861Type
ArticleLanguage
enISSN
0009-9260ae974a485f413a2113503eed53cd6c53
10.1016/S0009-9260(05)82928-9
Scopus Count
Collections
Related articles
- [Diagnosis of colorectal tumors].
- Authors: Vogl TJ, Pegios W, Jacobi V, Schäfer S, Abolmaali N, Luboldt W
- Issue date: 2003 Feb
- [Preoperative staging of rectal cancer with computed tomography].
- Authors: Briccoli A, Beghi M, Farinetti A, Ricchi E, Guernelli N
- Issue date: 1989 Jul
- An Unexpected Recurrence After Endoscopic Resection of Low-Risk T1 Colorectal Cancer.
- Authors: Dang RH, Boonstra JJ, Langers AMJ
- Issue date: 2019 Jul
- Staging rectal carcinoma with endorectal imaging: how much detail do we really need?
- Authors: de Lange EE
- Issue date: 1994 Mar
- CT and MR imaging in the staging of colorectal carcinoma: report of the Radiology Diagnostic Oncology Group II.
- Authors: Zerhouni EA, Rutter C, Hamilton SR, Balfe DM, Megibow AJ, Francis IR, Moss AA, Heiken JP, Tempany CM, Aisen AM, Weinreb JC, Gatsonis C, McNeil BJ
- Issue date: 1996 Aug
Related items
Showing items related by title, author, creator and subject.
-
Treatment for non small cell lung cancer, small cell lung cancer and pleural mesothelioma within the EORTC Lung Cancer Group: past, present and future.O'Brien, M; van Meerbeeck, J; Surmont, V; Faivre-Finn, Corinne (2012)
-
Ovarian cancer among 8,005 women from a breast cancer family history clinic: no increased risk of invasive ovarian cancer in families testing negative for BRCA1 and BRCA2.Ingham, S; Warwick, J; Buchan, I; Sahin, S; O'Hara, Catherine; Moran, Anthony; Howell, Anthony; Evans, D; Centre for Health Informatics, Institute of Population Health, The University of Manchester, Manchester, UK. (2013-06)Mutations in BRCA1/2 genes confer ovarian, alongside breast, cancer risk. We examined the risk of developing ovarian cancer in BRCA1/2-positive families and if this risk is extended to BRCA negative families.
-
AZD8186 study 1: phase I study to assess the safety, tolerability, pharmacokinetics (PK), pharmacodynamics (PD) and preliminary anti-tumour activity of AZD8186 in patients with advanced castration-resistant prostate cancer (CRPC), squamous non-small cell lung cancer, triple negative breast cancer and with PTEN-deficient/mutated or PIK3CB mutated/amplified malignancies, as monotherapy and in combination with vistusertib (AZD2014) or abiraterone acetate.Lillian, S; De Bono, J; Higano, C; Shapiro, G; Brugger, W; Mitchell, P; Colebrook, S; Klinowska, T; Barry, S; Dean, Emma J; et al. (2016-12)